December 2024: Volume 9, Issue 3
Regulatory Pathway for Cell and Gene Therapies in the United States: Perspectives from Innovators and Investors
Cheyenne Ariana Erika Modina, Sandra Waugh Ruggles, and Josh Makower, Stanford University
Regi’s “Innovating in Healthcare” Cases: GoodRx
A Requiem for Value-Based Care
Kevin Schulman, Stanford School of Medicine
Applying Precedents Thinking to the Intractable Problem of Transaction Costs in Healthcare
Brooke Istvan, Perry Nielsen Jr, Megan Eluhu, Bryan Kozin, Walt Winslow, David Scheinker, Kavita Patel, Kenneth Favaro, Stefanos Zenios, and Kevin Schulman, Stanford University
The Reality of Medicare Part D Drug Price Negotiations Under the Inflation Reduction Act
Markus Saba, Tanya Aggarwal, Ashwin Ramanathan, and Stewart Spanbauer, UNC Kenan-Flagler Business School
Revisiting Direct-to-Consumer and Pharmacy Advertising: 2024 Lessons from the Rise of Anti-Obesity Medicines
Avik Ray, Brigham and Women’s Hospital, and Chirantan Chatterjee, University of Sussex Business School
Why AI Is Good for Our Health but May Hurt Our Wallets
Sneha S. Jain, Morgan Cheatham, Bessemer Venture Partners, Michael A. Pfeffer, Linda Hoff, and Nigam H. Shah, Stanford University
Pinar Karaca-Mandic: Researcher, Entrepreneur & CEO
Pinar Karaca-Mandic, Carlson School of Management, University of Minnesota, and Kirsten Gallagher, Managing Editor, HMPI
Better Health Economics: An Introduction for Everyone
Tal Gross, Professor, Department of Markets, Public Policy & Law, Questrom School of Business, Boston University
Insured But Not Protected: Business Model Innovation and Stabilizing Healthcare Premium Inflation for All Americans
Ernest G Ludy, Founding CEO, Medstat Systems; Senior Advisor, Clinical Excellence Research Center, Stanford University